Verseon granted two important US patents

4th Jan 2017 12:32

(ShareCast News) - Technology-based pharmaceutical company Verseon announced on Wednesday that the United States Patent and Trademark Office has granted US Patents No. 9,533,967 and 9,533,970, which cover various aspects of multiple families of compounds that were designed by the company for its drug programs.The AIM-traded firm had previously obtained patent protection in China, New Zealand, Israel, and Australia related to the subject matter of US Patent 9,533,967.It said that among other aspects, the patents demonstrate the novelty and nonobviousness of compounds related to Verseon's anticoagulant programme.In preclinical studies, its oral direct thrombin inhibitors reportedly demonstrated efficacy comparable to current anticoagulants along with reduced bleeding risk.They are expected to enter clinical trials in 2017."The newly issued patents are an important milestone in our ongoing effort to strengthen the intellectual property protection for our drug programs in key markets," said co-founder David Kita."We expect to receive further patents in the near future."Our anticoagulant candidates have the potential to change the standard of care for millions of patients with thrombosis-related disorders."